Among these targets, five of them (A2AR/ADORA2A, CSK, CYP24A1, BRDT, and BRAF) have been suggested in recent scientific papers to be related to prostate cancer and all can interact with ligands with known therapeutic advantages against advanced prostate cancer. The gene discussed is BRAF; the disease is prostate carcinoma.